(NASDAQ: BLRX) Biolinerx's forecast annual revenue growth rate of 25.15% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 34.98%, and while it is forecast to beat the US market's average forecast revenue growth rate of 9.26%.
Biolinerx's revenue in 2024 is $17,048,000.On average, 2 Wall Street analysts forecast BLRX's revenue for 2024 to be $25,502,527,877, with the lowest BLRX revenue forecast at $21,041,531,571, and the highest BLRX revenue forecast at $29,963,524,183. On average, 2 Wall Street analysts forecast BLRX's revenue for 2025 to be $28,718,037,966, with the lowest BLRX revenue forecast at $27,017,470,247, and the highest BLRX revenue forecast at $30,418,605,685.
In 2026, BLRX is forecast to generate $43,256,694,384 in revenue, with the lowest revenue forecast at $43,256,694,384 and the highest revenue forecast at $43,256,694,384.